Rizik od infekcije gripom kod starijih osoba i uloga vakcinacije u prevenciji i smanjenju komplikacija
Sažetak
Uvod
Grip predstavlja ozbiljnu pretnju za starije osobe zbog oslabljenog imunološkog sistema i komorbiditeta. Ljudi stariji od 65 godina suočavaju se s povećanim rizikom od komplikacija, uključujući hospitalizacije, kardiovaskularne probleme, pneumoniju i smrt. Prema podacima Svetske zdravstvene organizacije (WHO), grip uzrokuje između 250.000 i 500.000 smrtnih slučajeva godišnje, od čega je u Evropi procenjeno 38.500.
Cilj rada
Istražiti rizike koje grip nosi starijoj populaciji, s fokusom na komorbiditete i uticaj vakcinacije u smanjenju tih rizika, kao i prednosti novih vakcina za ovu rizičnu grupu.
Diskusija
Rizik od komplikacija raste s godinama i pratećim bolestima. Kardiovaskularne komplikacije, uključujući srčane udare i pogoršanje srčane insuficijencije, često su posledica infekcije gripom. Pneumonija je vodeći uzrok smrtnosti, a javlja se kod 10% zaraženih. Iako imunološki odgovor kod starijih na vakcine može biti slabiji, istraživanja pokazuju da vakcinacija značajno smanjuje rizik od teških ishoda. Nova generacija vakcina, kao što su visoko-dozne i adjuvansne vakcine, poboljšava imunološki odgovor i zaštitu.
Zaključak
Vakcinacija protiv gripa pruža značajnu zaštitu starijim osobama, smanjujući ozbiljnost bolesti i stopu smrtnosti. Napredak u razvoju novih vakcina poboljšava ishode u ovoj rizičnoj grupi, čineći vakcinaciju ključnom strategijom u prevenciji komplikacija gripa.
Ključne reči: virus gripa, influenca, vakcinacija, stari, komlikacije, efikasnost vakcine
Reference
2. Ferdinand KC, Nedunchezhian S, Reddy TK. The COVID-19 and influenza “Twindemic”: barriers to influenza vaccination and potential acceptance of SARS-CoV2 vaccination in African Americans. Journal of the National Medical Association. 2020 Dec 1;112(6):681-7.
3. Blank PR, van Essen GA, Ortiz de Lejarazu R, Kyncl J, Nitsch-Osuch A, Kuchar EP, Falup-Pecurariu O, Maltezou HC, Zavadska D, Kristufkova Z, Kassianos G. Impact of European vaccination policies on seasonal influenza vaccination coverage rates: An update seven years later. Human vaccines & immunotherapeutics. 2018 Nov 2;14(11):2706-14.
4. Antonelli Incalzi R, Consoli A, Lopalco P, Maggi S, Sesti G, Veronese N, Volpe M. Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion. Internal and Emergency Medicine. 2024 Apr;19(3):619-40.
5. Richter D. Gripa–mikrobiologija, imunologija i epidemiologija za liječnika koji razmišlja o cijepljenju. Liječnički vjesnik. 2018;140(11-12):321-7.
6. Vasileiou, Eleftheria. "Seasonal influenza vaccine effectiveness in asthma." (2019); 59.
7. Jurčević I. Prevencija epidemije uzrokovane virusom influence (Doctoral dissertation, University of Zadar. Department of Health Studies).2019;8-11.
8. Goeijenbier M, Van Sloten TT, Slobbe L, Mathieu C, Van Genderen P, Beyer WE, Osterhaus AD. Benefits of flu vaccination for persons with diabetes mellitus: a review. Vaccine. 2017 Sep 12;35(38):5095-101.
9. Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, Millett C. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. Cmaj. 2016 Oct 4;188(14):E342-51.
10. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA cardiology. 2016 Jun 1;1(3):274-81.
11. Restivo V, Costantino C, Bono S, Maniglia M, Marchese V, Ventura G, Casuccio A, Tramuto F, Vitale F. Influenza vaccine effectiveness among high-risk groups: A systematic literature review and meta-analysis of case-control and cohort studies. Human vaccines & immunotherapeutics. 2018 Mar 4;14(3):724-35.
12. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA cardiology. 2016 Jun 1;1(3):274-81.
13. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine. 2015 Aug 26;33(36):4565-71.
14.Costantino C, Vitale F. Influenza vaccination in high-risk groups: a revision of existing guidelines and rationale for an evi- dence-based preventive strategy. J Prev Med Hyg 2016; 57(1): E13-8; PMID:27346934
15.Effectiveness of influenza vaccination in the elderly: a population-based case-crossover study. BMJ Open, 2021. [BMJ Open](https://bmjopen.bmj.com/content/11/8/e049324)
16. Zivkovic I, Muhandes L, Petrusic V, Minić R, Dimitrijevic L. The effect of influenza vaccine immunization on natural antibodies. Arhiv za farmaciju. 2021;71:207-23.
17.Systematic review of the efficacy, effectiveness, and safety of newer and enhanced seasonal influenza vaccines. European Centre for Disease Prevention and Control (ECDC), 2020. [ECDC](https://www.ecdc.europa.eu/en/publications-data/systematic-review-efficacy-effectiveness-and-safety-newer-and-enhanced-seasonal)
18.World Health Organization. "Vaccines against influenza WHO position paper—November 2012." Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire 87.47 (2012): 461-476.
19. Domnich A, Cambiaggi M, Vasco A, Maraniello L, Ansaldi F, Baldo V, Bonanni P, Calabrò GE, Costantino C, de Waure C, Gabutti G. Attitudes and beliefs on influenza vaccination during the COVID-19 pandemic: results from a representative Italian survey. Vaccines. 2020 Nov 30;8(4):711.
20. CDC Director Adopts Preference for Specific Flu Vaccines for Seniors, [internet accessed on 09/08/2024], https://www.cdc.gov/flu/index.htm
21. Morse, Kristen, and Kevin W. Cleveland. "Efficacy of the adjuvanted influenza vaccine compared with the high-dose for older people." The Senior Care Pharmacist 38.4 (2023): 156-160.